Independent chairman of the board
Michel Baijot, PhD, is a bioengineer with over 25 years of experience in building biologicals businesses, making a significant contribution to strategy, licensing, M&A and technology transfer, with in-depth knowledge of developed and emerging markets. He is currently Board Director of Radiomics, White Fund, Sinovac, 20 Med Therapeutics and Flash Therapeutics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association for five years.
Representing the co-founders
Chief Executive Officer
Chief Commercial Officer
Chief Medical Officer
Chief Financial Officer
In 2007, he joined the IBA group,a leader in advanced radiotherapy and molecular imaging, as financial controller of the molecular imaging activities. During the 5 years spent within the IBA group, he actively participated in international strategic operations (financial, modeling, due diligence, negotiation, etc.), in business development activities (merger-acquisition, new products) while developing experience in planning, budgeting and control. In 2011, he joined the Sowalfin group where he spent around 2 years as a senior analyst working on the financing of innovative start-ups / spin-offs & SMEs.
In 2013, he started working as an independent CFO with various asssignments, particularly in the health / biotechnology sector: Cisbio Bio-Assays (France with subsidiaries in the United States and China), CHR Mons Hainaut, Bio-Sourcing , Elysia, ANMI,…. He joined the Radiomics team as CFO in August 2019.